Selected research
Market Structure
Global Peptide Therapeutics Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Peptide Therapeutics Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Peptide Therapeutics Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Peptide Therapeutics Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Peptide Therapeutics Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Peptide Therapeutics Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Peptide Therapeutics Drugs include Takeda, Teva, Sanofi, J & J, Novartis, Novo Nordisk, Merck, Eli Lilly and Ferring, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Peptide Therapeutics Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Peptide Therapeutics Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Peptide Therapeutics Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Peptide Therapeutics Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.
Peptide Therapeutics Drugs Segment by Company
Takeda
Teva
Sanofi
J & J
Novartis
Novo Nordisk
Merck
Eli Lilly
Ferring
AbbVie
AstraZeneca
The Medicines
Lantheus
Ipsen
CSL Vifor Group
BioMarin Pharmaceutical
Aurinia Pharmaceuticals
Apellis Pharmaceuticals
Peptide Therapeutics Drugs Segment by Type
Injection
Oral
Other
Peptide Therapeutics Drugs Segment by Application
Central Nervous System
Metabolic Disorders
Cancer
Other
Peptide Therapeutics Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Therapeutics Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Peptide Therapeutics Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Therapeutics Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Peptide Therapeutics Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Peptide Therapeutics Drugs industry.
Chapter 3: Detailed analysis of Peptide Therapeutics Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Peptide Therapeutics Drugsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Injection
- Oral
- Other
Applications
- Central Nervous System
- Metabolic Disorders
- Cancer
- Other
Companies covered
- Takeda
- Teva
- Sanofi
- J & J
- Novartis
- Novo Nordisk
- Merck
- Eli Lilly
- Ferring
- AbbVie
- AstraZeneca
- The Medicines
- Lantheus
- Ipsen
- CSL Vifor Group
- BioMarin Pharmaceutical
- Aurinia Pharmaceuticals
- Apellis Pharmaceuticals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Peptide Therapeutics Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Injection
- 1.2.3 Oral
- 1.2.4 Other
- 1.3 Market Analysis by Application
- 1.3.1 Global Peptide Therapeutics Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Central Nervous System
- 1.3.3 Metabolic Disorders
- 1.3.4 Cancer
- 1.3.5 Other
- 1.4 Global Market Growth Prospects
- 1.5 Global Peptide Therapeutics Drugs Growth Trends by Region
- 1.5.1 Global Peptide Therapeutics Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Peptide Therapeutics Drugs Market Size by Region (2021-2026)
- 1.5.3 Peptide Therapeutics Drugs Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Peptide Therapeutics Drugs Market Dynamics
- 2.1 Peptide Therapeutics Drugs Industry Trends
- 2.2 Peptide Therapeutics Drugs Industry Drivers
- 2.3 Peptide Therapeutics Drugs Industry Opportunities and Challenges
- 2.4 Peptide Therapeutics Drugs Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Peptide Therapeutics Drugs Revenue by Company (2021-2026)
- 3.2 Global Peptide Therapeutics Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Peptide Therapeutics Drugs Key Company Head office and Area Served
- 3.4 Global Peptide Therapeutics Drugs Company, Product Type & Application
- 3.5 Global Peptide Therapeutics Drugs Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Peptide Therapeutics Drugs Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Peptide Therapeutics Drugs Players Market Share by Revenue in 2025
- 3.6.3 2025 Peptide Therapeutics Drugs Tier 1, Tier 2, and Tier 3
4 Peptide Therapeutics Drugs Market by Type
- 4.1 Global Peptide Therapeutics Drugs Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Peptide Therapeutics Drugs Market Size by Type (2021-2032)
- 4.3 Global Peptide Therapeutics Drugs Market Size Share by Type (2021-2032)
5 Peptide Therapeutics Drugs Market by Application
- 5.1 Global Peptide Therapeutics Drugs Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Peptide Therapeutics Drugs Market Size by Application (2021-2032)
- 5.3 Global Peptide Therapeutics Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Takeda
- 6.1.1 Takeda Company Information
- 6.1.2 Takeda Business Overview
- 6.1.3 Takeda Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Takeda Peptide Therapeutics Drugs Product Portfolio
- 6.1.5 Takeda Recent Developments
- 6.2 Teva
- 6.2.1 Teva Company Information
- 6.2.2 Teva Business Overview
- 6.2.3 Teva Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Teva Peptide Therapeutics Drugs Product Portfolio
- 6.2.5 Teva Recent Developments
- 6.3 Sanofi
- 6.3.1 Sanofi Company Information
- 6.3.2 Sanofi Business Overview
- 6.3.3 Sanofi Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Sanofi Peptide Therapeutics Drugs Product Portfolio
- 6.3.5 Sanofi Recent Developments
- 6.4 J & J
- 6.4.1 J & J Company Information
- 6.4.2 J & J Business Overview
- 6.4.3 J & J Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 J & J Peptide Therapeutics Drugs Product Portfolio
- 6.4.5 J & J Recent Developments
- 6.5 Novartis
- 6.5.1 Novartis Company Information
- 6.5.2 Novartis Business Overview
- 6.5.3 Novartis Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Novartis Peptide Therapeutics Drugs Product Portfolio
- 6.5.5 Novartis Recent Developments
- 6.6 Novo Nordisk
- 6.6.1 Novo Nordisk Company Information
- 6.6.2 Novo Nordisk Business Overview
- 6.6.3 Novo Nordisk Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Novo Nordisk Peptide Therapeutics Drugs Product Portfolio
- 6.6.5 Novo Nordisk Recent Developments
- 6.7 Merck
- 6.7.1 Merck Company Information
- 6.7.2 Merck Business Overview
- 6.7.3 Merck Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Merck Peptide Therapeutics Drugs Product Portfolio
- 6.7.5 Merck Recent Developments
- 6.8 Eli Lilly
- 6.8.1 Eli Lilly Company Information
- 6.8.2 Eli Lilly Business Overview
- 6.8.3 Eli Lilly Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Eli Lilly Peptide Therapeutics Drugs Product Portfolio
- 6.8.5 Eli Lilly Recent Developments
- 6.9 Ferring
- 6.9.1 Ferring Company Information
- 6.9.2 Ferring Business Overview
- 6.9.3 Ferring Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Ferring Peptide Therapeutics Drugs Product Portfolio
- 6.9.5 Ferring Recent Developments
- 6.10 AbbVie
- 6.10.1 AbbVie Company Information
- 6.10.2 AbbVie Business Overview
- 6.10.3 AbbVie Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 AbbVie Peptide Therapeutics Drugs Product Portfolio
- 6.10.5 AbbVie Recent Developments
- 6.11 AstraZeneca
- 6.11.1 AstraZeneca Company Information
- 6.11.2 AstraZeneca Business Overview
- 6.11.3 AstraZeneca Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.11.4 AstraZeneca Peptide Therapeutics Drugs Product Portfolio
- 6.11.5 AstraZeneca Recent Developments
- 6.12 The Medicines
- 6.12.1 The Medicines Company Information
- 6.12.2 The Medicines Business Overview
- 6.12.3 The Medicines Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.12.4 The Medicines Peptide Therapeutics Drugs Product Portfolio
- 6.12.5 The Medicines Recent Developments
- 6.13 Lantheus
- 6.13.1 Lantheus Company Information
- 6.13.2 Lantheus Business Overview
- 6.13.3 Lantheus Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.13.4 Lantheus Peptide Therapeutics Drugs Product Portfolio
- 6.13.5 Lantheus Recent Developments
- 6.14 Ipsen
- 6.14.1 Ipsen Company Information
- 6.14.2 Ipsen Business Overview
- 6.14.3 Ipsen Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.14.4 Ipsen Peptide Therapeutics Drugs Product Portfolio
- 6.14.5 Ipsen Recent Developments
- 6.15 CSL Vifor Group
- 6.15.1 CSL Vifor Group Company Information
- 6.15.2 CSL Vifor Group Business Overview
- 6.15.3 CSL Vifor Group Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.15.4 CSL Vifor Group Peptide Therapeutics Drugs Product Portfolio
- 6.15.5 CSL Vifor Group Recent Developments
- 6.16 BioMarin Pharmaceutical
- 6.16.1 BioMarin Pharmaceutical Company Information
- 6.16.2 BioMarin Pharmaceutical Business Overview
- 6.16.3 BioMarin Pharmaceutical Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.16.4 BioMarin Pharmaceutical Peptide Therapeutics Drugs Product Portfolio
- 6.16.5 BioMarin Pharmaceutical Recent Developments
- 6.17 Aurinia Pharmaceuticals
- 6.17.1 Aurinia Pharmaceuticals Company Information
- 6.17.2 Aurinia Pharmaceuticals Business Overview
- 6.17.3 Aurinia Pharmaceuticals Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.17.4 Aurinia Pharmaceuticals Peptide Therapeutics Drugs Product Portfolio
- 6.17.5 Aurinia Pharmaceuticals Recent Developments
- 6.18 Apellis Pharmaceuticals
- 6.18.1 Apellis Pharmaceuticals Company Information
- 6.18.2 Apellis Pharmaceuticals Business Overview
- 6.18.3 Apellis Pharmaceuticals Peptide Therapeutics Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.18.4 Apellis Pharmaceuticals Peptide Therapeutics Drugs Product Portfolio
- 6.18.5 Apellis Pharmaceuticals Recent Developments
7 North America
- 7.1 North America Peptide Therapeutics Drugs Market Size (2021-2032)
- 7.2 North America Peptide Therapeutics Drugs Market Size by Type
- 7.2.1 North America Peptide Therapeutics Drugs Market Size by Type (2021-2026)
- 7.2.2 North America Peptide Therapeutics Drugs Market Size by Type (2027-2032)
- 7.2.3 North America Peptide Therapeutics Drugs Market Share by Type (2021-2032)
- 7.3 North America Peptide Therapeutics Drugs Market Size by Application
- 7.3.1 North America Peptide Therapeutics Drugs Market Size by Application (2021-2026)
- 7.3.2 North America Peptide Therapeutics Drugs Market Size by Application (2027-2032)
- 7.3.3 North America Peptide Therapeutics Drugs Market Share by Application (2021-2032)
- 7.4 North America Peptide Therapeutics Drugs Market Size by Country
- 7.4.1 North America Peptide Therapeutics Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Peptide Therapeutics Drugs Market Size by Country (2021-2026)
- 7.4.3 North America Peptide Therapeutics Drugs Market Size by Country (2027-2032)
- 7.4.4 North America Peptide Therapeutics Drugs Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Peptide Therapeutics Drugs Market Size (2021-2032)
- 8.2 Europe Peptide Therapeutics Drugs Market Size by Type
- 8.2.1 Europe Peptide Therapeutics Drugs Market Size by Type (2021-2026)
- 8.2.2 Europe Peptide Therapeutics Drugs Market Size by Type (2027-2032)
- 8.2.3 Europe Peptide Therapeutics Drugs Market Share by Type (2021-2032)
- 8.3 Europe Peptide Therapeutics Drugs Market Size by Application
- 8.3.1 Europe Peptide Therapeutics Drugs Market Size by Application (2021-2026)
- 8.3.2 Europe Peptide Therapeutics Drugs Market Size by Application (2027-2032)
- 8.3.3 Europe Peptide Therapeutics Drugs Market Share by Application (2021-2032)
- 8.4 Europe Peptide Therapeutics Drugs Market Size by Country
- 8.4.1 Europe Peptide Therapeutics Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Peptide Therapeutics Drugs Market Size by Country (2021-2026)
- 8.4.3 Europe Peptide Therapeutics Drugs Market Size by Country (2027-2032)
- 8.4.4 Europe Peptide Therapeutics Drugs Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Peptide Therapeutics Drugs Market Size (2021-2032)
- 9.2 China Peptide Therapeutics Drugs Market Size by Type
- 9.2.1 China Peptide Therapeutics Drugs Market Size by Type (2021-2026)
- 9.2.2 China Peptide Therapeutics Drugs Market Size by Type (2027-2032)
- 9.2.3 China Peptide Therapeutics Drugs Market Share by Type (2021-2032)
- 9.3 China Peptide Therapeutics Drugs Market Size by Application
- 9.3.1 China Peptide Therapeutics Drugs Market Size by Application (2021-2026)
- 9.3.2 China Peptide Therapeutics Drugs Market Size by Application (2027-2032)
- 9.3.3 China Peptide Therapeutics Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Peptide Therapeutics Drugs Market Size (2021-2032)
- 10.2 Asia Peptide Therapeutics Drugs Market Size by Type
- 10.2.1 Asia Peptide Therapeutics Drugs Market Size by Type (2021-2026)
- 10.2.2 Asia Peptide Therapeutics Drugs Market Size by Type (2027-2032)
- 10.2.3 Asia Peptide Therapeutics Drugs Market Share by Type (2021-2032)
- 10.3 Asia Peptide Therapeutics Drugs Market Size by Application
- 10.3.1 Asia Peptide Therapeutics Drugs Market Size by Application (2021-2026)
- 10.3.2 Asia Peptide Therapeutics Drugs Market Size by Application (2027-2032)
- 10.3.3 Asia Peptide Therapeutics Drugs Market Share by Application (2021-2032)
- 10.4 Asia Peptide Therapeutics Drugs Market Size by Country
- 10.4.1 Asia Peptide Therapeutics Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Peptide Therapeutics Drugs Market Size by Country (2021-2026)
- 10.4.3 Asia Peptide Therapeutics Drugs Market Size by Country (2027-2032)
- 10.4.4 Asia Peptide Therapeutics Drugs Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Peptide Therapeutics Drugs Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Peptide Therapeutics Drugs Market Size by Type
- 11.2.1 South America, Middle East & Africa Peptide Therapeutics Drugs Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Peptide Therapeutics Drugs Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Peptide Therapeutics Drugs Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Peptide Therapeutics Drugs Market Size by Application
- 11.3.1 South America, Middle East & Africa Peptide Therapeutics Drugs Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Peptide Therapeutics Drugs Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Peptide Therapeutics Drugs Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Peptide Therapeutics Drugs Market Size by Country
- 11.4.1 South America, Middle East & Africa Peptide Therapeutics Drugs Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Peptide Therapeutics Drugs Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Peptide Therapeutics Drugs Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Peptide Therapeutics Drugs Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst